Therapy and prevention of gastric ulcer.
After establishing the benign nature of a gastric ulcer, the treatment is primarily medical. This medical therapy is aimed to alleviate symptoms, to heal the ulcer and to prevent relapses. Based on the history of non-steroidal anti-inflammatory drugs (NSAIDs) and the Helicobacter pylori-status, gastric ulcer patients can be divided into four categories (1) H. pylori positive plus NSAID-use, (2) H. pylori positive without NSAID use, (3) NSAID use with negative H. pylori-status, (4) Negative H. pylori-status and no NSAID use. Patients taking NSAIDs should stop this therapy if possible. Patients with gastric H. pylori infection should be treated by a regimen of a proton pump inhibitor with at least two appropriate antibiotics. This treatment will result in early alleviation of symptoms, rapid healing of the ulcer and prophylaxis of ulcer relapse. In patients with gastric ulcer who cannot stop NSAIDs, maintenance therapy with prostaglandins or potent antisecretory drugs should be considered. The few patients with gastric ulcer who do not take NSAIDs and do not have gastric H. pylori infection should be treated by antisecretory drugs, and they should be carefully followed endoscopically to exclude malignant (carcinoma, lymphoma) or non-peptic (Crohn's disease) disease. All patients with gastric ulcer should be re-endoscoped to verify complete ulcer healing. Surgery may be considered in gastric ulcer patients with complications, in those with severe dysplasia of the gastric mucosa, and in those who are not able or willing to take the medication.
Lamers
C B
CB
Department of Gastroenterology-Hepatology, University Hospital, Leiden, The Netherlands.
Biemond
I
I
Masclee
A A
AA
Veenendaal
R A
RA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D005744:Gastric Acid / Q000378:metabolism / Q000502:physiology; D016481:Helicobacter Infections / Q000517:prevention & control / Q000628:therapy; D016480:Helicobacter pylori / Q000187:drug effects / Q000472:pathogenicity; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D013276:Stomach Ulcer / Q000517:prevention & control* / Q000628:therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006635:Histamine H2 Antagonists